• Isaac N Biney, Arzu Ari, Igor Z Barjaktarevic, Brian Carlin, David C Christiani, Lauren Cochran, M Bradley Drummond, Karmon Johnson, Dan Kealing, Philip J Kuehl, Jie Li, Donald A Mahler, Sergio Martinez, Jill Ohar, Lewis J Radonovich, Akshay Sood, Jason Suggett, Ruth Tal-Singer, Donald Tashkin, Julie Yates, Lisa Cambridge, Patricia A Dailey, David M Mannino, and Rajiv Dhand.
• University Pulmonary and Critical Care, The University of Tennessee Graduate School of Medicine, Knoxville, TN. Electronic address: IBiney@utmck.edu.
• Chest. 2024 Mar 1; 165 (3): 653668653-668.

BackgroundNebulizers are used commonly for inhaled drug delivery. Because they deliver medication through aerosol generation, clarification is needed on what constitutes safe aerosol delivery in infectious respiratory disease settings. The COVID-19 pandemic highlighted the importance of understanding the safety and potential risks of aerosol-generating procedures. However, evidence supporting the increased risk of disease transmission with nebulized treatments is inconclusive, and inconsistent guidelines and differing opinions have left uncertainty regarding their use. Many clinicians opt for alternative devices, but this practice could impact outcomes negatively, especially for patients who may not derive full treatment benefit from handheld inhalers. Therefore, it is prudent to develop strategies that can be used during nebulized treatment to minimize the emission of fugitive aerosols, these comprising bioaerosols exhaled by infected individuals and medical aerosols generated by the device that also may be contaminated. This is particularly relevant for patient care in the context of a highly transmissible virus.Research QuestionHow can potential risks of infections during nebulization be mitigated?Study Design And MethodsThe COPD Foundation Nebulizer Consortium (CNC) was formed in 2020 to address uncertainties surrounding administration of nebulized medication. The CNC is an international, multidisciplinary collaboration of patient advocates, pulmonary physicians, critical care physicians, respiratory therapists, clinical scientists, and pharmacists from research centers, medical centers, professional societies, industry, and government agencies. The CNC developed this expert guidance to inform the safe use of nebulized therapies for patients and providers and to answer key questions surrounding medication delivery with nebulizers during pandemics or when exposure to common respiratory pathogens is anticipated.ResultsCNC members reviewed literature and guidelines regarding nebulization and developed two sets of guidance statements: one for the health care setting and one for the home environment.InterpretationFuture studies need to explore the risk of disease transmission with fugitive aerosols associated with different nebulizer types in real patient care situations and to evaluate the effectiveness of mitigation strategies.Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.

19 keywords...

hide…